Transcatheter aortic valve implantation (TAVI) has become the standard treatment for patients with symptomatic severe aortic stenosis (AS) at elevated operative risk1,2, and new indications continue to emerge3. As the implementation of TAVI is expanding, controlling procedural complications is essential. Despite smaller profile devices and operator experience, recent trials have revealed that major bleeding and vascular complications are not uncommon, occurring in approximately 4-7% of cases4-6. These complications can frequently be attributed to inadequate vascular closure7. Moreover, this impacts on midterm and long-term clinical outcomes8.